Live
Promega BlogPromega Builds Opportunity to Appreciate Hidden WetlandFierceBiotechADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisonsBioPharma DiveEthyreal starts up with $101M and takes aim at a pair of immune diseasesClinical OMICsEngineered Salmonella Delivers Cancer-Killing Virus to TumorsEndpoints NewsNovartis and Orionis strike second molecular glue deal for $40M upfrontFierceBiotechGLP-1s may combat depression by multiplying a mood-boosting gut microbeBioPharma DiveSanofi stops immune drug trial in latest research setbackEndpoints NewsSonoThera raises $125M for non-viral gene therapy approachBioPharma DiveParabilis sets a record with a $670M biotech IPOFierceBiotechBig Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic deliveryClinical OMICsGLP-1s May Benefit Mental Health Through Gut–Brain AxisClinical OMICsPhase Ib/IIa for Hepatitis B Epigenetic Silencer Shows Best-in-Class Potential
FierceBiotech 5 déc. 2025

Cancer blood test developer Freenome to go public in $330M SPAC deal

Cancer blood test developer Freenome to go public in $330M SPAC deal

Original
Contenu indisponible. Consultez la source originale.